Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster Display session 3

2513 - The Immunoscore in patients with urothelial carcinoma treated with neoadjuvant chemotherapy: clinical significance for pathological response and survival

Date

30 Sep 2019

Session

Poster Display session 3

Topics

Tumour Site

Urothelial Cancer

Presenters

Elise Nassif

Citation

Annals of Oncology (2019) 30 (suppl_5): v356-v402. 10.1093/annonc/mdz249

Authors

E.F. Nassif1, B. Mlecnik2, C. Thibault3, X. Barthere4, M. Auvray3, D. Bruni2, E. Comperat5, A. Colau6, F. Hermitte7, P. Camparo8, P. Colin9, D. Bruno10, M. Bennamoun4, F. Audenet11, A. Mejean12, V. Verkarre13, R. Zakopoulou14, A. Bamias15, S. Oudard16, J. Galon17

Author affiliations

  • 1 Oncology, Paris Descartes University, 75006 - Paris/FR
  • 2 Laboratory Of Integrative Cancer Immunology, Inserm, 75006 - Paris/FR
  • 3 Oncology, Hopital European George Pompidou, 75015 - Paris/FR
  • 4 Medical Oncology, Institut Mutualiste Montsouris, 75014 - Paris/FR
  • 5 Ap-hp Service Of Pathology Tenon Hospital, Sorbonne University, GRC n°5, ONCOTYPE-URO, 75020 - PARIS/FR
  • 6 Urology, Diaconnesses, Paris/FR
  • 7 R&d, HalioDx, 13009 - Marseille/FR
  • 8 Pathology, Centre de Pathologie, 80000 - Amiens/FR
  • 9 Urology Department Saint-louis Hospital, Hôpital privé de la Louvière,., 59042 - Lille/FR
  • 10 Urology, saint jean de dieu, 75007 - Paris/FR
  • 11 Ap-hp, Urology Department, Georges Pompidou European Hospital, Université Paris Descartes, 75015 - PARIS/FR
  • 12 Urology, Paris Descartes University, 75006 - Paris/FR
  • 13 Patholoy, Hopital European George Pompidou, 75015 - Paris/FR
  • 14 Medical Oncology, University of Athens, 115 27 - Athens/GR
  • 15 Clinical Therapeutics, University of Athens, Sotiria General Chest Diseases Hospital, 11527 - Athens/GR
  • 16 Immunothérapie Et Traitement Antiangiogénique En Pathologie cancérologique, Hopital European George Pompidou, 75015 - Paris/FR
  • 17 Inserm Team 15, Laboratory of Integrative Cancer Immunology, 75006 - Paris/FR

Resources

Login to access the resources on OncologyPRO.

If you do not have an ESMO account, please create one for free.

Abstract 2513

Background

We investigated whether Imunoscore performed on localized or locally advanced urothelial carcinoma (UC) tumor samples could predict response to neoadjuvant chemotherapy and survival outcome.

Methods

This retrospective ongoing study evaluated the Immunoscore in 150 patients with UC (140 UC of the bladder, 10 UC of the upper tract) from 6 centers (Greece and France). All patients underwent neo-adjuvant chemotherapy. Pre-treatment tumor samples (trans-urethral resection or upper tract biopsy) were immunostained for CD3+ and CD8+ T cells and quantified by digital pathology to determine the Immunoscore. The consensus Immunoscore was applied to tumors with invasive margin and an Immunoscore adapted to samples quantified when no invasion was identified on the specimen. Results were correlated with response to neoadjuvant treatment and time to recurrence (TTR).

Results

Immunoscore Low, Intermediate and High were respectively observed in 40, 43 and 17% of the cohort. Densities of CD3 and CD8 in the center and invasive margin were not significantly different according to clinical parameters such as T-stage, N-stage, age, gender, tumor differentiation (with or without variant), and localization (upper tract versus bladder). Immunoscore was positively and significantly correlated with TTR. High, intermediate and low Immunoscore patients had a median TTR of 83, 34 and 27 months, respectively (P < 0,05). In multivariate analysis, Immunoscore remains a significant independent parameter at presentation associated with TTR (High vs Low: P < 0.05). Immunoscore was positively and significantly correlated with pathologic complete response (pCR) (P < 0.001). Low Immunoscore was observed in 69% of patients with no pCR, and in only 20% of patients with pCR. In contrast, high Immunoscore was observed in only 7% of patients with no pCR, whereas 40% of these patients had a pCR.

Conclusions

The results of this ongoing study show a significant prognostic and potentially predictive role of Immunoscore in UC patients with important therapeutic implications. These preliminary results will be completed as samples are being analyzed before ESMO 2019 annual meeting.

Clinical trial identification

Editorial acknowledgement

Legal entity responsible for the study

The authors.

Funding

FONCER.

Disclosure

C. Thibault: Honoraria (self), Travel / Accommodation / Expenses: Astellas Pharma; Honoraria (self): Ipsen; Advisory / Consultancy, Travel / Accommodation / Expenses: Janssen-Cilag; Advisory / Consultancy, Travel / Accommodation / Expenses: Pfizer; Advisory / Consultancy, Research grant / Funding (institution): Sanofi Pasteur; Research grant / Funding (institution), Travel / Accommodation / Expenses: AstraZeneca/Medimmune; Travel / Accommodation / Expenses: Astellas; Travel / Accommodation / Expenses: Roche/Genentech. F. Hermitte: Shareholder / Stockholder / Stock options, Full / Part-time employment: HalioDx. A. Bamias: Honoraria (self), Advisory / Consultancy, Research grant / Funding (self): BMS; Honoraria (self), Advisory / Consultancy, Research grant / Funding (self): Pfizer; Advisory / Consultancy, Research grant / Funding (self): AstraZeneca; Advisory / Consultancy, Research grant / Funding (self): Ipsen; Research grant / Funding (self): Lilly; Research grant / Funding (self): Astellas. J. Galon: Advisory / Consultancy, Research grant / Funding (institution), Shareholder / Stockholder / Stock options: HalioDx; Honoraria (self): AstraZeneca; Honoraria (self): Novartis; Honoraria (self): Merck; Honoraria (self): MSD; Honoraria (self): BMS; Honoraria (self): Sanofi; Honoraria (self): Gilead; Advisory / Consultancy, Research grant / Funding (institution): Io Biotech; Advisory / Consultancy: Illumina; Advisory / Consultancy: Northwest Biotherapeutics; Advisory / Consultancy: Actelion; Advisory / Consultancy: Amgen; Research grant / Funding (institution): Perkin Elmer; Research grant / Funding (institution): MedImmune; Research grant / Funding (institution): Janssen; Research grant / Funding (institution): Imcheck; Licensing / Royalties: INSERM. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.